Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Shares Issued (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Shares Issued for 12 consecutive years, with -$28.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Issued fell 122143.48% to -$28.1 million in Q4 2025 year-over-year; TTM through Sep 2025 was $28.1 million, a 95.62% decrease, with the full-year FY2024 number at $397.5 million, up 47.06% from a year prior.
  • Shares Issued was -$28.1 million for Q4 2025 at Madrigal Pharmaceuticals, down from $17.7 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $311.6 million in Q1 2024 to a low of -$129.7 million in Q3 2021.
  • A 5-year average of $52.9 million and a median of $14.1 million in 2025 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: soared 4429.4% in 2024, then tumbled 122143.48% in 2025.
  • Madrigal Pharmaceuticals' Shares Issued stood at $169.7 million in 2021, then plummeted by 94.72% to $9.0 million in 2022, then soared by 2627.11% to $244.2 million in 2023, then crashed by 100.01% to -$23000.0 in 2024, then crashed by 122143.48% to -$28.1 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Shares Issued are -$28.1 million (Q4 2025), $17.7 million (Q3 2025), and $10.4 million (Q2 2025).